Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
15 Results Found
AHA Urges Administration to Grant Exceptions for Tariffs for Medications and Medical Supplies
The AHA asks President Trump to consider granting exceptions to the current and proposed tariffs for medical devices and pharmaceuticals made in Mexico, Canada and China that are essential to the provision of safe, effective care in America's hospitals, clinics, and other settings.
AHA Urges HHS to Reject the Effort by Several Large Drug Companies to Undermine the 340B Drug Pricing Program
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”
High & Rising Drug Prices: Myth vs. Fact
Get the facts on 8 common misconceptions about the rising costs of prescription drugs.
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities.
Trump Administration Issues Order on Drug Pricing
The White House April 15 released an executive order, “Lowering Drug Prices by Once Again Putting Americans First,” directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription drugs.
AHA Comments on CMS Proposed Medicare Drug Pricing Model
AHA comments regarding the Centers for Medicare & Medicaid Services Medicare $2 Drug List (M2DL) Model request for information (RFI).
CMS Finalizes Guidance on Implementation of the Medicare Drug Price Negotiation Program
The Centers for Medicare & Medicaid Services (CMS) Oct. 2 released its final guidance on implementing the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program.
Affordability Advocacy Agenda
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and equity into our policy and advocacy activities.
Drug Prices
Hospitals bear a heavy financial burden when the cost of drugs increases. They are not only major purchasers of drugs, but patients often end up in the hospital when they cannot afford to take their medications as prescribed. To that end, the American Hospital Association is proud to be a member of the Campaign for Sustainable Rx Pricing -– a diverse coalition of doctors, hospitals, pharmacists, employers, health plans, seniors, patients, consumers and others coming together to find common ground and solutions.
Fact Sheet: Advocacy Priorities for Fall 2022
America’s hospitals and health systems continue to deal with the difficult challenges of high inflation and ongoing effects of the COVID-19 pandemic. Specifically, hospitals are facing significant increases in costs of labor from workforce shortages, drugs, equipment and supplies (including food and energy costs) that are threatening their stability and ability to provide access to high quality health care services. The AHA has developed resources that hospital leaders can use to advocate on these important issues.